Fundraising Fox

Avalyn Pharma Inc

NASDAQ: AVLN

63 employees on LinkedIn · 20 known investors

Find your way into Avalyn Pharma Inc

423 people in our graph share verified history with the Avalyn Pharma Inc team — schools, employers, funds. One of them is your warm intro.

Micah Rosenbloomunlockedknows Lyn Baranowski · together at Harvard Business School (overlapped)
×7knows the team · via Harvard Business School
×4knows the team · via American University

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.

BiotechHealthtech

Founders & leadership

LBLyn Baranowski
Lyn BaranowskiinCEOLyn Baranowski holds an MBA from Harvard Business School and brings over 20 years of biopharma experience to her role as CEO of Avalyn Pharma, having previously held leadership positions in the development and commercialization of respiratory and specialty therapies at other companies, and led multiple M&A transactions in the sector.

Investors · 20

Andera PartnersParis
Catalio Capital Management, LPNew York
F-Prime CapitalCambridge · $3M – $10M
InVivium CapitalChicago
Norwest Venture PartnersMenlo Park · $10M – $30M
RiverVest Venture PartnersSt. Louis · $500K – $3M
SR One Capital ManagementRedwood City
Vida VenturesLos Angeles
Catalio Capital ManagementreportedNew York
Novo Holdingsreported · 2 sourcesCopenhagen · $1.1M – $54M
Perceptive Xontogeny VenturereportedNew York
Pivotal Life SciencesreportedSan Francisco
Rock Springs CapitalreportedBaltimore
T. Rowe PricereportedBaltimore
Wellington ManagementreportedBoston · $5M – $50M

Also in the syndicate · 5

Eventide Asset ManagementleadPerceptive Xontogeny Venture FundsleadPiper HeartlandSR OneleadSurveyor Capital (a Citadel Company)

Funding

SEC filings, press & company announcements

$445.4M disclosed across 2 of 6 rounds · 1900–2026

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events
$752.7Mvaluation at IPOApr 2026 · $18.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 5

by search overlap
Alnylam26 shared keywordsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
Eli Lilly17 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Bioworld15 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eledon15 shared keywordsEledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS. The company's lead candidate is tegoprubart, an anti-CD40L antibody.
Robinhood14 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies competing with Avalyn Pharma Inc for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Avalyn Pharma closes $345 million IPO on Nasdaq By Investing.cominvesting.com · May 2026Avalyn Pharma Raises $300 Million in Upsized US IPO Backed by Novo Holdings - Bloombergbloomberg.com · Apr 2026Novo-Backed Respiratory Drugmaker Avalyn Pharma Files for US IPOfinance.yahoo.com · Apr 2026About | Avalyn Pharma Incavalynpharma.com · Jul 2024Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studiesglobenewswire.com · Sep 2023

Frequently asked questions

What does Avalyn Pharma Inc do?
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.
Who are Avalyn Pharma Inc's investors?
Avalyn Pharma Inc's investors include Andera Partners, Catalio Capital Management, LP, F-Prime Capital, InVivium Capital, Norwest Venture Partners, RiverVest Venture Partners, SR One Capital Management, Vida Ventures and 7 more.
How much funding has Avalyn Pharma Inc raised?
Avalyn Pharma Inc has disclosed $445.4M raised across 2 of its 6 known rounds.